JCM Figure table search 04
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Krajden, M.
Right arrow Articles by Kapke, G. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krajden, M.
Right arrow Articles by Kapke, G. F.

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, February 1998, p. 382-386, Vol. 36, No. 2
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Assessment of Hepatitis B Virus DNA Stability in Serum by the Chiron Quantiplex Branched-DNA Assay

Mel Krajden,1,2,* Lorraine Comanor,3 Oretta Rifkin,1 Anna Grigoriew,1 James M. Minor,3 and Gordon F. Kapke4

Department of Microbiology, The Toronto Hospital and Toronto Medical Laboratories,1 and Department of Clinical Biochemistry, University of Toronto,2 Toronto, Ontario, Canada; Chiron Diagnostics, Emeryville, California3; and Covance Central Laboratories (formerly Corning, Scicor Inc.), Indianapolis, Indiana4

Received 4 August 1997/Returned for modification 26 September 1997/Accepted 30 October 1997

Quantification of hepatitis B virus (HBV) DNA in serum is used to establish eligibility for treatment and to monitor therapeutic response. With the trend toward centralized testing, defining the conditions that preserve sample integrity is of paramount importance. We therefore evaluated the stability of HBV DNA in 26 previously frozen (PF) and 5 fresh, never previously frozen serum specimens. PF specimens, covering a 3-log10 HBV DNA dynamic range, were thawed and stored at -70, 4, 23, 37, and 45°C (±1.5°C) for 0, 24, 72, and 120 h (±2 h) and were refrozen at -70°C prior to testing. Five fresh specimens were split into two groups. Both group FG1 and group FG2 specimens were handled as described above; however, group FG1 specimens were subsequently maintained at 4°C and were never frozen prior to testing. Linear regression analysis of PF specimens demonstrated no significant HBV DNA degradation at <= 4°C over 5 days; however, HBV DNA levels decreased by 1.8, 3.4, and 20% per day at 23, 37, and 45°C, respectively. Three independent statistical methods confirmed that the probability of specimen failure, defined as a loss of 20% or more of HBV DNA and/or coagulation of serum, was lowest at <= 4°C and increased with temperature. Because only 10 to 20% of individual patient specimens demonstrated losses of HBV DNA of >= 20% at 23 or 37°C, sufficient numbers of serum specimens must be evaluated to determine overall statistical trends. In conclusion, HBV DNA integrity in separated serum specimens is preserved for at least 5 days when the specimens are stored at -70 or 4°C.


* Corresponding author. Mailing address: The Toronto Hospital, Department of Microbiology, 13-NU-102, 200 Elizabeth St., Toronto, Ontario, Canada M5G 2C4. Phone: (416) 340-3336. Fax: (416) 971-6362. E-mail: mkrajden{at}torhosp.toronto.on.ca.


Journal of Clinical Microbiology, February 1998, p. 382-386, Vol. 36, No. 2
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev.
Clin. Vaccine Immunol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.